Philippe Vanhille - Publications

Tubulointerstitial damage and interstitial immune cell phenotypes are useful predictors for renal survival and relapse in antineutrophil cytoplasmic antibody-associated vasculitis.

Journal: Journal of nephrology

Published: September 27, 2019

MYH9-related disorders display heterogeneous kidney involvement and outcome.

Journal: Clinical kidney journal

Published: May 09, 2018

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 19, 2017

A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)

Published: March 13, 2016

Course of chronic kidney disease in French patients.

Journal: Clinical kidney journal

Published: January 15, 2016

Clinical and mutational spectrum of hypoparathyroidism, deafness and renal dysplasia syndrome.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: December 21, 2015

Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.

Journal: PloS one

Published: December 02, 2015

Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.

Journal: Kidney international

Published: October 27, 2015

Mutation Update of the CLCN5 Gene Responsible for Dent Disease 1.

Journal: Human mutation

Published: February 11, 2015

Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.

Journal: Journal of the American Society of Nephrology : JASN

Published: February 01, 2015

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Journal: Blood

Published: May 30, 2014

Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 26, 2014